Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?
Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year prior ts2.tech. It traded near the bottom of its 52-week range ($20.92 – $30.43), weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospects ts2.tech ts2.tech. In fact, Pfizer’s COVID-driven revenues
